Wockhardt

India pharma majors Dr Reddy's, Wockhardt, and others deny allegations of conspiracy to fix prices in US

The generic drug makers are named in an anti-trust lawsuit in the US on allegations of engaging in a conspiracy to fix prices

Wockhardt Uses Analytics To Increase Profit Margin

Avadhut Parab, Deputy General Manager – IT, Wockhardt highlights how pharma cos leverage innovative technologies while high-lighting on-going IT initiatives at Wockhardt.

US FDA issues warning letter to Wockhardt’s Ankleshwar plant

US FDA has already banned import of products from the facility into the US market since 5 August 2016

Wockhardt looking to raise Rs 1,200 cr via NCDs to repay debt

The company said it will utilise the money to re-pay or pre-pay term loan availed by it and for general corporate purposes

Sun, Wockhardt recall drugs from US market

Bupropion is an antidepressant used to treat major depressive disorder and seasonal affective disorder.

Wockhardt hopes to resolve FDA ban on two plants in FY16

Wockhardt has been hit by slowing sales in the US ever since the FDA banned exports from the company's Waluj and Chikalthana plants in Maharashtra in 2013, citing production quality lapses.

Mid-cap pharma shares buck weak sentiment; Aurobindo, Wockhardt up nearly 3%

Recovery in mid-cap pharma shares comes even as the benchmark Sensex and other key indices continue to linger in negative territory

Wockhardt recalls 12-15 drugs from US market; shares tumble up to 11%

The company clarified to CNBC-TV18 that it has taken measures to resolve the FDA's concerns

Nifty Changes: DLF, JSPL to be replaced by Yes Bank and Idea Cellular

Realty major DLF and Naveen Jindal-led Jindal Steel & Power will be dropped from the National Stock Exchange's benchmark index Nifty from 27 March.

Earnings: Wockhardt Q3 profit up 14% to Rs 347.25 cr

Wockhardt Ltd today reported 14.05 percent increase in consolidated net profit at Rs 347.25 crore for the third quarter ended December 31, 2014-15.